Optum

Understanding topical medications

Workers' compensation and auto no-fault



March 2022

Topical medications

- What are they?
- When and why are they used?
- What are they made from?



Topical medications are applied to the skin or mucous membranes for the purpose of treating pain or other medical condition affecting a specific area of the body.



What are they and why use topical medications?

- May be prescription or over-the-counter medications
- Could be commercially available or compounded by a pharmacy
- Often contain more than one active ingredient, but not always
- Used when an alternative to the oral delivery of medications is needed
- Might have a decreased potential for adverse effects associated with an oral therapy for a certain injured party or population of patients
- Potentially play an increased role in treatments for a catastrophically injured claimant or in one with co-morbid conditions that cause dysphagia (difficulty swallowing); thus, the topical route offers ease of administration
- Are more common in pediatric or geriatric medicine

Topical medication use in injuries

- Generally considered second- or third-line treatments in nationally recognized guidelines and state-based formularies or medical treatment protocols
- Could be helpful as industry shifts away from the use of opioid analgesics for pain associated with conditions that are non-terminal, yet chronic in nature
- Use may be complicated depending on how the medication is used by the body to elicit its actions
- Often include the use of compounded medications, individualized for the injured worker
- May wish to look for an OTC alternative, especially for the commercially available products
- Care should be given to look for duplications of therapy with oral or injectable medications



Some potential concerns with topical medications

- In certain states of jurisdiction, prescribers and smaller pharmacies have identified a niche based on workers' compensation rules
- May be very high in cost
- Efficacy may not be established for some injured parties
- Compounding practice guidelines are typically overseen by state boards of pharmacy
- May have limited shelf life / use life that drives refills
- Limited state and federal guidance to address compounding regulations. This is changing in recent years and many of the state formularies are not allowing compounded medications, such as:



Compounded medication regulations



Not addressed by specific WC regulations/fee schedules

- Unique state compounded medications reimbursement/billing qualifiers and/or provisions
- Individual ingredient(s) NDC required on compounded medications bills
- Language explicitly permits denial of reimbursement for individual ingredients lacking an NDC

* Additional state regulatory/statutory billing and payment requirements, which may include prior authorization.

Data - Reflects published statutes/regulations/fee schedules related to workers' compensation compounded medication billing/reimbursement. Current as of January 2023.

Physician dispensing / repackaging restrictions



Note – States such as AR, DE, FL, KY, NY, and TN have overlapping workers' compensation and state Practice Act controls. Data – Reflects published state statutes/regulations/case law on Physician Dispensing/Repackaging. Current as of **January 2023**.

- Workers' compensation statutes/regulations limit physician dispensing and/or repackaging (restrictions on dispensing, billing and/or reimbursement)
- Legal restrictions (Practice Act) in addition to workers' compensation controls
- Legal restrictions on physician dispensing (Practice Act)
- No clear legal or workers' compensation limits on physician dispensing and/or repackaging

Compounded medications

- Types
- Therapeutic concerns
- Considerations



Types of compounded medications

Sterile products

- Intended to be delivered by injection or used in the eye/ear
- Must be manufactured under strict sterility and compounding guidelines
- Governed by state and local entities and industry groups
- Examples:
 - Injectable formulations (for example, highly concentrated morphine) for infusion pumps or epidural steroid injections

Non-sterile products

- Generally topical, suppositories, or oral formulations
- Not required to be produced in a sterile environment
- Examples:
 - Topical formulations applied to the skin, often to treat nerve, muscle, or joint pain (examples: muscle relaxants, analgesics, anticonvulsants)
 - Oral compounded formulations used for local or systemic absorption (examples: capsules, solutions, suspension, lozenges)
 - Suppositories used for local or systemic absorption (for example, rectal application)

Compounded medications are personalized for patients and include ingredients in the exact strength and dosage form for their specific needs

- Require a prescription; the active ingredients in compounded medications are usually prescription medications combined together
- Compound products themselves are not FDA approved; however, individual ingredients typically are FDA approved
- Are largely experimental in use with few randomized controlled trials to determine efficacy or safety
- Are not commercially available and are typically much more expensive than their oral formulation counterparts
 - Recent regulatory changes by states are aimed at controlling the costs of compounded medications and ensuring patient safety

Common topical ingredients

On average, there are 4 to 5 individual ingredients in compounded medications.

Therapeutic class	Commonly used agents
NSAIDs	Ibuprofen, diclofenac, ketoprofen, flurbiprofen
Opioid analgesics	Tramadol, loperamide
Local anesthetics	Lidocaine, benzocaine, ketamine
Antidepressants	Amitriptyline, nortriptyline
Anticonvulsants	Gabapentin, Lyrica [®]
Skeletal muscle relaxants	Cyclobenzaprine, baclofen
Other topical analgesics	Clonidine

Safety of topical compounded medications

- The unique nature of how medication is absorbed through the skin presents concerns about the actual dose received during each application.
- Topical compounded medications are promoted as safer, due to less absorption than with oral medications, but there is little evidence to back this claim.
- There is potential for drug-drug interactions if the injured party is taking other medications and within the compound itself.
- Adverse effects from a compounded medication are difficult to tie back to a specific ingredient.

Compounded medications may be appropriate in therapy when...

- A commercial product is unavailable from the manufacturer.
 - <u>https://www.accessdata.fda.gov/scripts/drugshortages/</u>
- The treatment of the injury requires a specialty mix of medications.
- Typical administration of the drug therapy is unsuitable or ineffective.
 - Side effects
 - Allergies
 - Difficulty swallowing
 - Absorption issues
- Other therapies have documented failures.

Efficacy of compounded medications

Therapeutic class	ODG recommendation for topical use					
Non-steroidal anti-inflammatory drug (NSAID)	 Recommended after trial of oral NSAIDs for short-term use 1-2 weeks for acute pain from soft tissue injuries (strain/sprain) or prolonged use in osteoarthritis Compound not recommended First line: Diclofenac (Diclofenac 1% gel) 					
Local anesthetics	 Lidocaine recommended after trial for localized neuropathic pain after 2 trials of anticonvulsant/antidepressant have failed Compound not recommended First line: lidocaine 5% ointment or patch 					
Tricyclic antidepressants (TCAs)	Not recommended, inconsistent results					
Skeletal muscle relaxants	Not recommended, no peer reviewed literature					

Official Disability Guidelines recommendations

Ingredient	Recommendation					
Gabapentin and other AC	Not recommended as there is no peer-reviewed literature to support use.					
Ketoprofen	Not recommended; this has a high incidence of photo contact dermatitis and topical treatments can result in systemic effects comparable to oral forms.					
Capsaicin	Option for claimants who have not responded to or are intolerant of other treatments.					
Cyclobenzaprine	Not addressed in topical application. Cyclobenzaprine as an oral form is recommended as an option, using a short course of therapy, however, the addition of cyclobenzaprine to other agents is not recommended.					
Piroxicam	Not recommended, this is known to produce drug-induced photo contact dermatitis.					
Ketamine	Only recommended for treatment of neuropathic pain in refractory cases in which all primary and secondary treatments have been exhausted.					
Flurbiprofen	Not addressed in guidelines.					
Baclofen	Not recommended, there is no peer-reviewed literature to support use.					

Compounded pain creams case study

February 2019

A randomized controlled trial of **399 patients** with neuropathic (n=133), nociceptive (n=133), or mixed pain (n=133)

- Patients randomized to pain creams compounded for neuropathic pain (ketamine, gabapentin, clonidine, and lidocaine), nociceptive pain (ketoprofen, baclofen, cyclobenzaprine, and lidocaine), or mixed pain (ketamine, gabapentin, diclofenac, baclofen, cyclobenzaprine, and lidocaine), or placebo
- Measured pain score at baseline and 1 month post treatment

Results:

- No differences found in pain reduction between placebo and treatment groups
- At one month, 72 participants (36%) in the treatment groups and 54 (28%) in the control group had a positive outcome

Source: https://annals.org/aim/article-abstract/2724041/compounded-topical-pain-creams-treat-localized-chronic-pain-randomized-controlled

Private label topicals and topical compounded medication kits

Private label topicals

- Topical (ointment, cream, gel, patch) that is premade with a single NDC and therefore not considered compounded medication
- Commercially available and often physician dispensed
- Ingredients include a combination of over-the-counter ingredients
- Not FDA-approved or clinically tested for safety and efficacy
- Not recommended by evidence-based guidelines such as Official Disability Guidelines and American College of Occupational and Environmental Medicine

Examples of private label topicals

Brand name	Menthol	Methyl salicylate	Capsaicin	Camphor	Lidocaine	AWP† per 4 oz or 5-15 patches (Note: multiple bottles or boxes are often dispensed at a time)
Terocin Lotion	10%	25%	0.03%	-	2.50%	\$398.50
New Terocin Lotion	10%	25%	0.03%	-	-	\$487.00
Terocin Patch	4%	-	-	-	4%	\$485.00 (10/box)
Dendracin Neurodendraxcin Lotion	10%	30%	0.03%	-	-	\$464.40
Menthocin Patch	5%	20%	0.04%	-	0.50%	\$454.50 (15/box)
Medrox-Rx Ointment	7%	20%	0.05%	-	-	\$375.00
Avalin Patch	4%	-	-	-	4%	\$462.64 (15/box)
imencin Lotion	10%	25%	0.03%	-	-	\$487.42
Medi-Derm Cream	5%	20%	0.04%	-	-	\$389.00
Medi-Derm/L; Medi-Derm/L-Rx Cream	5%	20%	0.04%	-	2%	\$398.69
Menthoderm Ointment	10%	15%	-	-	-	\$488.26
Medi-Patch/Lidocaine or Medi-Patch	5%	20%	0.04%	-	0.50%	\$220.00 (5/box)
LenzaPro Patch	4%	-	-	-	4%	\$753.49 (15/box)
_idopro Ointment	10%	27.50%	0.03%	-	4%	\$485.88
idopro Patch	5%	4%	-	-	4%	\$720.00 (15/box)
idothol Pad	5%	-	-	-	4.50%	\$745.00 (15/box)
Nulido Gel	1%	-	-	-	4%	\$499.82
JItracin Lotion	10%	28%	0.03%	-	-	\$492.00
Exoten-C Lotion	10%	20%	0.00%	-	-	\$394.34
Koten-C Lotion	10%	20%	0.00%	-	-	\$382.85
Renovo Patch	5%	-	0.04%	-	-	\$573.60 (15/box)
Ist Medx-Patch with Lidocaine	5%	20%	0.04%	-	4%	\$450.00 (10/box)

[†]Average Wholesale Price, July 2019; per 4 oz. or 5–15 patches as package sizes vary

NOTE: Multiple bottles or boxes are often dispensed at one time.

Disclaimer: Not all commercially available topical analgesics are represented in this chart. Additionally, not all products have registered trademarks.

Examples of private label topicals and their alternatives

Private label topicals

Brand name	Menthol	Methyl salicylate	Capsaicin	Camphor	Lidocaine	AWP†
Terocin Lotion	10%	25%	0.03%	-	2.50%	\$398.50
Terocin Patch	4%	-	-	-	4%	\$485.00 (10/box)
Nulido Gel	1%	-	-	-	4%	\$499.82

Alternative medications

Brand name (manufacturer)	Menthol	Methyl salicylate	Capsaicin	Camphor	Lidocaine	AWP [†]
Aspercreme® with Lidocaine cream (Chattem, Inc.)					4.0%	\$6.30 (2 oz.)
Aspercreme® with Lidocaine patch (Chattem, Inc.)					4.0%	\$7.08 (5/box)
Greaseless BENGAY [®] Cream (Johnson & Johnson)	10.0%	15.0%				\$3.95 (2 oz.)
Icy Hot [®] Cream (Chattem, Inc.)	10.0%	30.0%				\$4.91 (3 oz.)
Icy Hot [®] Patch (Chattem, Inc)	5.0%					\$5.48 (5/box)
Icy Hot [®] with Lidocaine Cream (Chattem, Inc.)	1.0%				4.0%	\$6.60 (3 oz.)
Ultra Strength BENGAY [®] Cream (Johnson & Johnson)	10.0%	30.0%		4.0%		\$6.97 (4 oz.)
Muscle Rub Ultra Strength Cream (AmerisourceBergen)	10.0%	30.0%		4.0%		\$7.99 (4 oz.)
ZIKS Arthritis Pain Relief Cream (Nnodum Corp)	1.0%	12.0%	0.025%			\$25.99 (2 oz.)
Salonpas [®] Pain Relief Patch (Hisamitsu America, Inc.)	3.0%	10.0%				\$10.36 (10/box)
Salonpas [®] Lidocaine 4% Patch					4.0%	\$9.98 (6/box)
Capsaicin Cream (Ferndale Laboratories, Inc.)			0.025%			\$9.95 (2 oz.)
Capsaicin Hot Patch (Rite Aid Corp)			0.025%			\$2.39 (3/box)

[†]Average Wholesale Price, July 2019; per 4 oz. or 5–15 patches as package sizes vary

NOTE: Multiple bottles or boxes are often dispensed at one time.

Disclaimer: Not all commercially available topical analgesics are represented in this chart. Additionally, not all products have registered trademarks.

Topical compounded medication kits

- Combined kits for topical, oral, and injectable medications with single NDC
- May be difficult to identify in medical records
- Often listed as EnovaRx, Active Kit, Active Prep Kit, or just an ingredient without a dose or dosage form
- Most commercial plans are not covering these items
- Prescribing information supplied with these kits is for the oral formulations
- Compounded medication kits are considered investigational as they do not have a confirmed FDA approval
 of use



Topical compound medication kit examples

These are not recommended as many of the contained ingredients are not supported for topical use.

Enova-Rx lidocaine HCL 5% (60 grams)	EnovaRx-amitriptyline 2% Kit (120 grams)	Lorvatus PharmaPak Combination Kit 800
 Base cream plus lidocaine 	 Base cream plus amitriptyline 	 Metaxalone 800 mg #60 oral tabs and dialatanaa 4.5% 450 ml taniaal adution
Single NDC	Single NDC	diclofenac 1.5% 150 ml topical solution
• AWP* = \$298	• AWP* = \$513	 Single NDC with two products AWP* = \$6,488

NSAIDs case study

October 2013

Randomized, double-blind, Phase III trial of **555 patients** with American College of Rheumatology-defined Osteoarthritis of the knee and moderate pain comparing topical ketoprofen gel with ketoprofen-free gel

- Patients were randomized to receive either of the following topical medications, twice daily, for 12 weeks
 - 100 mg ketoprofen in 4.4 g Transfersome gel (IDEA-033)
 - 4.4 g ketoprofen-free vehicle (TDT 064)
- The primary endpoint was mean change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale score from baseline to week 12
- IDEA-033 was inferior to the drug-free gel in relieving moderate OA knee pain and improving joint function

RESULTS:

No difference in adverse effects

Source: http://www.jrheum.org/content/40/10/1742.long

Systemic review of topical agents

May 2017

A systemic review conducted on the efficacy of topical therapy in acute and chronic pain, primary outcome was \geq 50% pain reduction

206 studies and 30,700

patients evaluated comparing topical analgesic (NSAID, lidocaine, clonidine, capsaicin and salicylate to placebo or a comparable oral agent)

- Of all the NSAIDs studied, only 2 showed greater efficacy in acute nociceptive pain relief, diclofenac and ketoprofen compared to placebo
- When comparing oral NSAIDs to topical NSAIDs, no difference in efficacy was found
- Lidocaine was found to provide superior efficacy to placebo for neuropathic pain
- Evidence for other agents was of very low quality

Source: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008609.pub2/full https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007400.pub3/full





Monitoring medical necessity

- Did you confirm with prescriber that the topical medication is medically necessary?
- Have you reviewed available medical records and/or prescription history?
- Are there patient-specific issues that make use of the commercially prepared agents harmful?
- Have you consulted with a clinical pharmacist?



Questions to ask while managing your claims

- Did you confirm with prescriber that the topical medication is medically necessary?
- Have you reviewed available medical records and/or prescription history?
- Are there patient-specific issues that make use of the commercially prepared agents harmful? Unable to take oral medications?
- Have you consulted with a clinical pharmacist?
- Has the injured person tried and failed with commercially available medications?
- Have first-line oral agents been tried, failed, or unavailable?
- Is there a comorbid condition that prevents oral therapy from being tried first?
- Does the injured party have a documented allergy to commercially available products?
- Have other non-compounded topical medications been tried?

Questions to ask while managing your claims

- Have the individual ingredients within the compound been compared to ensure there is not duplicate therapy? Consider escalating to a clinical resource or a pharmacist for review.
- Is the condition being treated compensable?
- If compensable, are the ingredients appropriate for the condition being treated?
- Are the individual ingredients within the compound recommended by evidence-based guidelines such as Official Disability Guidelines (ODG) and American College of Occupational and Environmental Medicine (ACOEM)?



About Optum Workers' Comp and Auto No-Fault Solutions

Optum Workers' Comp and Auto No-Fault Solutions collaborates with clients to lower costs while improving health outcomes for the injured persons we serve. Our comprehensive pharmacy, ancillary, medical services, and settlement solutions, combine data, analytics, and extensive clinical expertise with innovative technology to ensure injured persons receive safe, appropriate and cost-effective care throughout the lifecycle of a claim. For more information, email us at expectmore@optum.com.

© 2023 Optum, Inc. All rights reserved. All other brand or product names are trademarks or registered marks of their respective owners. Optum continuously improves our products and services and reserves the right to change specifications without prior notice. PHM-23-1750